The FDA has not approved any drugs for treating behavioral symptoms of dementia, though atypical antipsychotics are commonly used. Studies show these drugs are associated with greater mortality. This study examined mortality risks of individual antipsychotic agents using VA data on 33,604 dementia patients aged 65+ who were prescribed risperidone, olanzapine, quetiapine, haloperidol, or valproic acid. Haloperidol had the highest 180-day mortality rate, followed by risperidone, olanzapine, valproic acid, and quetiapine, which had the lowest risk.